The RUFUS Study

The aim of this trial is to determine whether flumazenil can be given effectively and safely to patients with reduced consciousness following suspected benzodiazepine overdose.

RUFUS logo

Chief Investigator: Professor Michael Eddleston

Number and location of participating sites (by region/ country): UK 4 sites

ISRCTN number: 14373275

 

Funder:  Medical Research Council (MRC) DPFS

 

Start and End date

Of grant award: 01 Feb 2024 – 31 Jul 2028

Of recruitment:

23 Jan 2025 to 28 Feb 2026 (Stage 1 recruitment completed on 18th Dec 2025)

27 Feb 2026 - 31 Mar 2027 (Stage 2)

01 Apr 2027 - 31 Jan 2028 (Stage 3)

 

Current Status: Recruiting to Stage 2

Trial Website: https://cardiovascular-science.ed.ac.uk/rufus-trial

 

UK GDPR Privacy Statement: Within patient information booklet

 

Sponsor: ACCORD https://www.accord.ed.ac.uk/

 

Chief Investigator:  Professor Michael Eddleston, Centre for Cardiovascular Science, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh BioQuarter, Edinburgh, EH16 4TJ 

 

Trial Manager:  Edinburgh Clinical Trials Unit, Usher Building, The University of Edinburgh, 5‒7 Little France Road,  Edinburgh BioQuarter ‒ Gate 3 EDINBURGH EH16 4UX Email: rufus.trial@ed.ac.uk

 

ECTU involvement: Trial Management / Statistics / Database and randomisation service provision

This article was published on